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Summary
Background; The combination of anthracyclines and taxanes is
currently considered the first choice chemotherapy in advanced
breast cancer (ABC) and considerable emphasis has been
placed on programs exploring the safest and most efficient
way to integrate these classes of drugs in both the metastatic
and, more recently, the adjuvant setting.
We report here the overall results of the combination of
epidoxorubicin (E) 90 mg/m2 and docetaxel (D) 75 mg/m2 as
first-line chemotherapy in ABC.
Patients and methods; A total of 70 patients were entered in
the initial dose-finding study (20 patients) and in the subse-
quent extended phase II trial (50 patients). Overall 54% of
patients had dominant visceral disease and 57% had at least
two metastatic sites. Adjuvant anthracyclines were allowed in
the phase II part of the study based on the lack of cardiac
toxicity observed in the phase I study at a median cumulative E
dose of 480 mg/m2. A maximum of eight cycles of the combi-
nation was allowed, and cardiac function was monitored at
baseline and after every second course by echocardiography.
Results: Overall, the median number of cycles administered
with the combination was 4 (range 3-8). Neutropenia was
confirmed to be the main haematological toxicity, with
granulocyte colony-stimulating factor (G-CSF) support re-
quired in 44% of the cycles. Febrile neutropenia occurred in
12% of cycles of the combination but 52% of the episodes
could be managed on an outpatient basis with oral antibiotics.
Overall, the median cumulative dose of E, including prior
adjuvant anthracyclines, was 495 mg/m2 (range 270-1020
mg/irr). One patient who received adjuvant E together with
radiotherapy to the left chest wall developed fully reversible
clinical signs of cardiotoxicity and a significant decrease of
LVEF to 35% after a cumulative E dose of 870 mg/m2, with
four additional patients (6%) developing asymptomatic and
transient decline of resting LVEF. The overall response rate
(ORR) in 68 evaluable patients was 66% (95% confidence
interval (95% CI): 54%-73%). A comparable antitumour
activity of 71% was reported in the group of patients with a
prior adjuvant chemotherapy with anthracyclines. After an
overall median follow-up time of 22 months (range 4-39+),
the median time to progression (TTP) was 4.5 months and the
median duration of response was 8 months (range 3-16).
No pharmacokinetic (Pk) interaction could be demonstrated
between E and D when given simultaneously and sequentially
with a one-hour interval.
Conclusions: The combination of E and D in a multi-
institutional setting is an active and safe regimen in poor-
prognosis patients with ABC. New combinations and schedules
are worth considering in an attempt to further improve disease
response and long-term control of the disease.
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Introduction
First-line metastatic or ABC are the optimal settings
for testing new agents and combinations in controlled
clinical trials in order to assess their real impact on
long-term control of the disease and palliation of its
symptoms. Until recently, doxorubicin (Dox) was the
most active single agent available and anthracycline-
containing regimens have been considered the treatment
of choice as first- and second-line therapy of advanced
disease [1, 2].
In the 1990s, the taxanes [3], in particular D [4],
emerged as the most powerful new single agent in the
management of breast cancer [5, 6]: the high ORR con-
firmed in different studies, the lack of complete cross-
resistance and of significant toxicity have prompted the
evaluation of various combination regimens of these two
classes of drugs [7, 8]. The International Breast Cancer
Study Group (IBCSG) conducted a dose-finding phase I
trial of E and D as first-line therapy in ABC [9]: the ED
combination proved to be an effective and safe regimen
in poor-prognosis, anthracycline-naive patients. The lack
of both cumulative haematological toxicity and clinical
cardiac toxicity after four cycles of the combination led
to a phase II trial to evaluate a more protracted treat-
ment with the administration of higher cumulative doses
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of ED, also in patients who had received adjuvant
anthracyclines. We report the overall results of admin-
istration of the ED combination at the recommended
dose level of E 90 mg/m2 and D 75 mg/m2, established
in the dose-finding part of the study.
In addition we report the absence of any Pk interaction
between E and D given simultaneously or sequentially
with a one-hour interval.
Patients and methods
Patients with histologically or cytologically documented metastatic or
locally advanced breast cancer without prior chemotherapy for meta-
static disease were eligible. Neo/adjuvant chemotherapy completed at
least 12 months prior to study entry was allowed, a previous treatment
with anthracyclines qualified patients for the phase II trial provided
the total cumulative dose of Dox or E did not exceed 240 mg/m2 or
430 mg/m2, respectively, taking a conversion factor for cardiotoxicity
of 1.8, as previously discussed [9]. Prior hormonal therapy for advanced
disease was allowed. Eligibility criteria included adequate hematologic
(absolute neutrophil count (ANC) 5=2.0 x 109/l, platelet count (Pt)
> 100 x 109/l) renal, hepatic (liver function tests currently recom-
mended for treatment with D) [10] and cardiac function (LVEF
S= 50% by echocardiography), measurable or evaluable disease, and
written informed consent.
Baseline evaluation was performed during the four weeks before
study entry and included patient history, physical examination, chest
X-ray, complete blood cell count (CBC), biochemistry, electrocardio-
gram (ECG) echocardiogram (ECHO) and radiological imaging of
indicator lesions (CT scan, bone scan and/or X-rays of hot spots).
During therapy, CBC was performed at least twice weekly and bio-
chemistry before each cycle. Tumour response of measurable and
evaluable sites of disease and cardiac function monitoring (ECG and
ECHO) were repeated after every other course. Treatment was discon-
tinued in instances of CHF of any grade and/or of a significant
reduction in LVEF (3s 10% decrease from baseline associated with a
decline to a level < 50%) confirmed by an ECHO performed one week
later.
In the dose-finding part of the trial patients were allowed a
maximum of four cycles of the combination followed by four cycles of
single-agent D in case of response. Based on the observed lack of
significant cardiac toxicity, in the phase II study responders could
receive a total of eight cycles of the combination, up to a maximum
cumulative dose of E of 970 mg/m2 (corresponding to 540 mg/m2 of
Dox).
Response was defined according to WHO criteria [II]. Imaging of
all cases was reviewed by two external radiologists. The duration of
response was calculated from first demonstration of response to docu-
mented disease progression. TTP was dated from initial treatment to
progression, last contact or start of further antitumour therapy. Osteo-
lytic lesions were considered evaluable. but not measurable, while
sclerotic metastases were deemed not evaluable.
D (Taxotere) (RP 56976) was supplied by Aventis as a concentrated
sterile solution containing 40 mg/ml = 80 mg/2 ml/vial in polysorbate
80 (Tweenk 80). The appropriate solvent for the premix solution of D
was also supplied as a sterile solution in vials of 6 ml containing Ethyl
alcohol 95%: water 13: 87 (W/W).
E (farmorubicin RTU) is supplied in vials containing 10 mg, 20 mg.
and 50 mg of epidoxorubicin hydrochloride as a ready to use solution.
E was administered intravenously as a 15-minute infusion followed
after 1-hour interval by D given as a 1-hour infusion on Day 1. A 3-day
prophylactic medication with oral dexamethasone (8 mg b.i.d) 13
hours, 7 hours and 1 hour before D and then on days 1 and 2 was
routinely administered in combination with oral cimetidine (300 mg)
once daily. Prophylactic antiemetic treatment was given according to
the investigators' routine practice. Prophylactic oral antibiotics were
strongly recommended in instances of ANC below 0.5 x 10'/l. Therapy
was administered in the outpatient clinic every three weeks, provided
the ANC was >2.0 x 109/l and the Pt count was > 100 x 1O9/1 on the
day scheduled for retreatment. If recovery had not occurred after a
maximum delay of three weeks patients were withdrawn from the
study.
Toxicity was recorded according to the NCI-Common Toxicity
Criteria (CTC). Each cycle was considered fully evaluable for haema-
tological toxicity only in cases of an at least twice weekly CBC assess-
ment.
G-CSF support (150 ug/m2/day subcutaneously from day 2-11)
was initiated in individual patients at the subsequent cycle in instances
of febrile neutropenia (ANC <0.5 x 1O9/I and single elevation in oral
temperature to >38.5°C during a 24-hour period) [12] or failure of
ANC recovery by the day of retreatment. The E dose was decreased
to 75 mg/m2 in instances of grade 4 thrombocytopenia, grade > 3
non-haematological toxicity (except for alopecia, nausea/vomiting,
musculoskeletal pain), persistence of grade 5=2 nonhematologic
toxicity at scheduled retreatment or febrile neutropenia despite G-CSF
support
Pharmacokinetics
Pk of both E and D when given in combination was investigated in a
subset of 12 patients who were randomly allocated to receive the
combination according to two different schedules: group A: E 90
mg/m2 given first, followed after one hour, by D 75 mg/m"; group B:
E given as above, immediately followed by D. The one-hour interval
between the two drugs (group A) was selected to assess the potential
influence of a delay in the administration of D on the Pk profile of
both drugs. With this purpose, E, its major metabolite 13-hydroxy-
epidoxorubicin (epidoxorubicinol) and D were measured in plasma at
the following time points: To (pretreatment), end of the anthracycline
infusion and at 0.25, 0 5, 1, 1.5, 2, 3, 4, 8, 24 and 48 hours after the end
of E administration.
Drug concentrations were assayed in plasma by high-performance
liquid chromatography (HPLC) after solvent extraction for the anthra-
cyclines, and after solid phase extraction for D [13, 14] The limit of
quantitation (LOQ) for E and D were 2 and 15 ng/ml. respectively.
The Pk parameters were obtained by fitting the concentration-time
data for both drugs on a non-linear fitting program [15], calculating the
experimental area under the curve of the plasma concentration versus
time (AUC) by the trapezoidal method from 0 to the last time point
available (Cz) with concentration above the LOQ, plus the extrapo-
lated portion of the curve to infinity obtained dividing Cz by the
elimination phase konstant (Kel).
Results
From October 1996 to May 1998, a total of 70 patients
with metastatic or locally ABC were treated with E 90
mg/m2 and D 75 mg/m2, 20 in the phase I part of the
study and 50 in the extended phase II program. The
median follow-up time is 22 months (range 4-39+). The
patients'characteristics (Table 1) were similar in the two
studies, with the results of the phase I having already
been reported [9]. Overall, 38 patients (54%) had domi-
nant visceral disease and 40 (57%) had at least two
metastatic sites. A total of 417 courses of therapy were
administered, of which 369 (88%) were with the combi-
nation and 48 (12%) with single-agent D; 326 cycles
with ED (88%) were fully evaluable for haematological
toxicity, as no dose reductions were applied and a twice
weekly CBC was performed. Treatment delays occurred
in 12% of cycles (32 patients), most of them because of
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Table 1. Patient characteristics. Table 2. Overall neutropema and related complications.
Number of patients (%)
Entered and evaluable
Age
Median
Range
Dominant disease site
Viscera (liver)
Locoregional
Soft tissue
Bone
Oestrogen receptor
Pos
Neg
Unknown
Number of metastatic sites
1
S*2
Prior adjuvant chemotherapy
With anthracyclines
Prior hormonal treatment
Metastatic
50
21-68
70
38 (25)
21
5
6
33
24
13
30
40
29
7
20
3
No
G-CSF
With
G-CSF
Table 3
Phase I
Phase 11
No. of No. of
cycles cycles
(eval) ED
(eval)
417(371) 369(326)
234(200) 192(161)
183(171) 177(165)
Median
nadir ANC
(109/l)
(range)
0.28
(0.01-3 57)
0.16
(0.01-2 37)
0.66
(0.03-3.57)
ANC
<0.5.
median
duration
(days)
(range)
3(0-12)
4(0-12)
0 (0-8)
Grade ^ 2 non-hematologic toxicities.
Nausea/
vomiting
(% cycles)
7
11
Asthenia
(% cycles)
7
8
Febrile
neutro-
penia
(%
cycles)
12
24
3
Mucositis
(% cycles)
9
8
Grade 4
• ANC
(%
cycles)
64
88
41
Myalgia
(% cycles)
2
3
logistical problems (77%), followed by haematological
(12%), or non-haematological (4%) toxic effects, or
other causes (7%). G-CSF was given during 183 cycles
(44%) in 47 patients due mainly to haematological tox-
icity (febrile neutropenia and prolonged G4 neutropenia
in 73% and 21% of cases, respectively). E dose reduction
was applied to six patients (14 cycles) as a consequence
of either febrile neutropenia despite G-CSF support (3
patients), or of grade 3 stomatitis and diarrhoea (2 and 1
patients each). E was definitively stopped in 10 patients
after 4 cycles (cumulative dose reached in 2 patients,
investigator's decision in the remaining 8). A total of 13
patients in the dose-finding part of the study (9 achieving
a PR and 4 with SD) received additional cycles of single-
agent D (4 and 2 cycles in 5 and 8 patients, respectively).
Overall, the median number of cycles administered
(including those with single-agent D) was 6 and the
median number of cycles with the combination was 4.
Haematological toxicity
Grade 4 neutropenia represented the main haematolog-
ical toxicity (Table 2) and occurred in about 60% of
cycles. The administration of G-CSF significantly re-
duced the incidence of both Grade 4 neutropenia, which
was reported in 41% and 88% of cycles with and without
G-CSF, respectively, and febrile neutropenia. Overall,
febrile neutropenia complicated 12% of cycles with ED
(44 cycles) and in 56% of cases occurred after the first
cycle, thereby confirming the overall incidence reported
in the phase I study (13%), but it was short lasting and
uncomplicated in the majority of patients; 52% of the
febrile episodes did not require hospitalisation and were
treated with oral antibiotics. G-CSF seemed to prevent
neutropenic fever when administered to patients who
had developed profound and long-lasting neutropenia
in previous cycles: in the group of G-CSF treated
patients the incidence of febrile neutropenia was 3%.
Grade 3-4 anemia and thrombocytopenia occurred in
only four patients and two patients, respectively, and
were of no clinical significance.
Non-haematological toxicity
All patients were evaluable for non-haematological
toxicity. Nonhematological toxicity was generally mild
to moderate, aside from alopecia which was complete
and universal (Table 3). Asthenia was common and
occasionally severe, especially in the early days follow-
ing corticosteroid interruption. Mucositis, neurotoxicity,
fluid retention, arthralgia and myalgia were present in
some patients but severe in < 10% of cycles. Two patients
experienced Grade 3-4 diarrhoea, in association with
grade 2 stomatitis and febrile neutropenia in one of them.
Cardiac toxicity
Overall, the median cumulative dose of E, including
prior adjuvant anthracyclines, was 495 mg/m2 (range
270-1020 mg/m2). The median LVEF assessed at base-
line was 63%; the echocardiographic evaluation was
repeated at the end of treatment in 93% of patients and
showed no alterations in the overall median determina-
tions (60%). Four patients (6%) developed a grade 2
asymptomatic and transient decline of resting LVEF by
more than 20% after cumulative doses of E ranging
from 360 mg/m2 to 720 mg/m2 (Table 4 and 5) with a
persistent absolute fall below 50% in only one patient.
One further patient who three years earlier had received
adjuvant E (420 mg/m2) together with radiotherapy to
the left chest wall developed atrial fibrillation and acute
lung oedema in association with a significant decrease of
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Table 4. Cardiac function according to CTC.
No. of Mean
patients Epi
(evaluable) (mg/m2
0 (%) I (%) I (%)
Phase I 20(18) 380
Median no. of
cycles 6
Phase II 50(47) 560
Median no. of
cycles 6
10(56) 7(39) 1(5) 0
6 6 NA(4) NA
22(47) 21(45) 3(6) 1(2)
6 6 6 NA(5)
Abbreviation: NA - not applicable
Table 5. Characteristics of patients with grade > 2 cardiac toxicity.
Age Risk Pre-th Post-th Total E Months Follow-up
factors0 LVEF LVEF (mg/m2) from LVEF(%)
(%) (%) start (months)
Phase 1 59 No
Phase II 57
45
64
56
No
No
No
Yes
65
65
69
80
60
47
51
51
60
58
360
525
720
360
870
46(7)
57(13)
64(12)
>60(20)
35(8)
60(16)
Risk factors (left chest wall radiotherapy, advanced age, diabetes).
Table 6. Antitumour activity.
Phase I (%) Phase II (%)
Entered/evaluable
CR
PR
SD
PD
Overall
20/19
0
11(58)
7(37)
1(5)
19(100)
50/49
3(6)
31(63)
9(19)
6(12)
49(100)
LVEF to 35% after a cumulative E dose of 870 mg/m2.
The clinical picture completely recovered under medical
treatment and LVEF returned to pretreatment values.
Antitumour activity
Of the 70 patients entered, two were not evaluable for
response because of an absence of measurable/evaluable
disease and 65 of 68 who were evaluable for response
had at least one measurable lesion. The ORR was 66%
(95% confidence interval (95% CI): 54%-73%) with
three patients (5%) achieving a complete remission
(CR) and seven patients (10%) showing tumour progres-
sion (PD) (Table 6). The median time to best response
was 83 days and the overall TTP was 4.5 months.
Duration of response was censored in 32 of 45 responders
due to the addition of maintenance hormonal therapy
(20 patients), surgical treatment (4 patients), different
chemotherapy (2 patients), combined chemo-hormono-
therapy (2 patients), surgery followed by endocrine
therapy (3 patients) and alternative therapy (1 patient).
In the remaining 13 patients the median duration of
response was 8 months (range 3-16 months). Adjuvant
chemotherapy did not seem to affect antitumour activity:
overall, in the 29 patients with prior adjuvant treatment
completed at least 12 months before starting ED (median
29 months, range 6-180), the ORR was 76%; of 7
patients who had received prior anthracyclines, none
has showed a PD while on treatment, 3 have achieved a
PR and 2 a CR for an ORR of 71%. All sites of disease
responded to treatment; overall there was an ORR in
visceral disease of 71%, (64% and 76% in patients with
lung and liver involvement, respectively) and 1 CR of 14
months' duration in 1 patient with liver metastases.
When E and D were given as neoadjuvant treatment in
locally advanced disease (12 patients) a PR was achieved
in 58%, after a median number of five cycles adminis-
tered (range 3-6). In the phase II study responders could
receive up to 8 cycles of the combination; in only 6
(18%) of the 34 patients who received more than 4 cycles
of ED the response improved under prolonged therapy,
while in 18 (40%) of 45 responding patients a PR was
already achieved after the first 2 cycles.
After a median follow-up time of 22 months (range
4-39+) 28 patients (40%) had died and 42 (60%) are still
alive: the two-year survival is 60%.
Pharmacokinetics
A comparison between the mean ± SD plasma decay
curves of E and epidoxorubicinol in 12 patients receiving
the treatment with two sequences of administration
(groups A and B) is shown in Figure la and lb. A similar
comparison is reported for D in Figure 2: the mean Pk
profile of D is shown in 11 patients only, due to the
insufficient amount of plasma available in 1 patient. No
significant differences in patients' characteristics which
could possibly interfere with the Pk profile of both drugs
(i.e., disease extent, concomitant medications, kidney
and liver function) were present.
E disappeared from plasma following the usual three
open compartment model showing no difference be-
tween the two sequences of treatment of drug and
metabolite plasma levels. Main Pk parameters of E
(mean ± SD) Cmax, AUC and terminal half-life were
5.62 ± 1.60 ug/ml, 3.32 ± 0.61 ug/ml/h and 20.9 ± 9.1
hours, after treatment A, and 5.64 ± 1.7 ug/ml, 3.21 ±
0.64 ug/ml/h and 20.2 ± 6.8 hours, after treatment B.
Similarly, no difference was found in the Pk profile of
epidoxorubicinol, with an AUC and a terminal half life
of 1.0 ± 0.48 ug/ml/h and 22.2 ± 7.9 hours, in group A,
and 1.0 ± 0.33 ug/ml/h and 20.6 ± 7.0 hours, in group B.
The main Pk parameters of D were similar when the
drug was administered one hour after E or simultaneously
with it. Cmax, AUC and T/2 were 2.0 ± 0.6 ug/ml, 2.55 ±
0.78 ug/ml/h and 10.6 ± 4 hours in group A and 1.8 ± 0.69
ug/ml, 2.82 ± 1.0 ug/ml/h and 12 ± 6 hours in group B.
Discussion
The previously published results of the phase I study
showed that the combination of E and D could be given
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Figure 1. Mean (± SD) plasma decay curves of E (a) and epidoxorubi-
cinol (b) determined in 12 patients who received E and D given
simultaneously (open symbol) or sequentially with a one-hour interval
(closed symbol).
safely at doses of 90 mg/m2 and, respectively, 75 mg/m2,
with neutropenia as the dose-limiting toxicity (DLT) [9].
Those findings are confirmed in the present cumulative
series: 44% of cycles required the administration of
G-CSF, motivated in two-thirds of the patients by the
occurrence of febrile neutropenia which complicated 12%
of cycles but was easy to handle with no septic deaths.
The prophylactic administration of oral antibiotics
during grade 4 neutropenia, the biweekly laboratory
assessment and the careful clinical evaluation in experi-
enced cancer centres may explain this favourable clinical
outcome. G-CSF significantly reduced haematological
complications and might be advisable for administration
of the combination in the general population. Adjuvant
chemotherapy might influence the severity of neutro-
penia with 76% of patients requiring G-CSF support
(86% and 73% of patients with and without prior
anthracycline-containing regimens), as compared with
61% in chemotherapy-naive patients.
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Figure 2 Mean (± SD) plasma decay curves of D determined in 11
patients who received E and D given simultaneously (open symbol) or
sequentially with a one-hour interval (closed symbol).
At the median cumulative dose of E of 495 mg/m2
(range 270-1020 mg/m") and with a median number of
cycles of the combination of 4, only one patient with a
previous history of both adjuvant anthracyclines and
radiotherapy to the left chest wall developed clinical
signs of cardiotoxicity together with a transient decline
in LVEF. Although prolonged observation indicates that
effects on myocardial contractility are reversible after
the end of combination therapy with Dox and paclitaxel
(P) [16], its potentially significant cardiotoxicity [17] has
introduced the concept of decreasing the safe cumula-
tive dose of Dox from the classical 500-550 mg/m2 to
360 mg/m2 when used with P given over three hours.
The identification of baseline risk factors (i.e., left chest
wall radiotherapy, advanced age, diabetes) [18, 19] could
help in both identifying the optimal patient population
and in implementing guidelines for appropriate dose
reductions. Several strategies to prevent cardiotoxicity
are also under evaluation [20, 21] and will likely allow
higher cumulative doses of P in combination with Dox
to be delivered.
Previous studies by Gianni et al. showed that the
combination of P and Dox was complicated by a signifi-
cant incidence of cardiac toxicity, possibly due to a Pk
interaction [22, 23]. In preclinical studies we showed
that tissue cardiac levels of Dox and E were significantly
increased in mice treated with P over those treated with
Dox alone [13]. It was therefore speculated that P could
inhibit the MDR.-related efflux mechanism mediated by
P-glycoprotein or other proteins known to be involved
in anthracyclines efflux, thereby increasing the tissue
distribution. This hypothesis led us to investigate the
possible Pk interaction between E and D, when E was
given immediately or one hour before D. The one-hour
interval was considered adequate to allow anthracycline
distribution without interference by the taxane.
The data obtained in this study, however, showed the
990
same Pk profile of both E and its metabolite epidoxo-
rubicinol, when E was given simultaneously or one hour
after D. Noteworthy is the fact that the levels were also
comparable to those reported in patients receiving E
alone at the same dose [24]. The lack of Pk interaction
between D and E is also supported by some recent data
obtained in mice showing that E distribution in several
tissues, including heart, was not affected by D [25].
The contrasting ability of P and D to interact with E
was also recently reported by Esposito et al. who found
in breast cancer patients much greater metabolic changes
of E when given with P rather than with D [26].
The ORR of 66% in 68 evaluable patients, treated in a
multi-institutional setting involving 6 centers, compares
favourably with the most recent data published on the
ED combination [27, 28] which used E doses ranging
from 60-80 mg/m2. As regards Dox-D combinations
the ORR of published data [29-33] ranged from 55%-
78% with slightly higher CR rates (5%-21%) at roughly
comparable dose levels (Dox from 40-60 mg/m2, D
from 50-75 mg/m2). However, in the only published
study [33], despite a reported longer overall TTP (11.5
months vs. 4.5 months in the present population), the
two-year survival is comparable (66% vs. 60% in the
present study). A direct comparison between the two
combinations in a randomised phase II trial could be of
interest.
In an attempt to further improve long-term control of
the disease and the toxicity profile a dose-finding study
is ongoing to combine fluoropyrimidines with weekly ED.
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